Table 1. PDL1 expression and clinicopathological features.
| Characteristics | PDL1 expression groups | ||||
|---|---|---|---|---|---|
| N | not-up (N = 366) | up (N = 87) | p | ||
| Median age, years (range) | 207 | 65 (32-88) | 64.5 (44-84) | 0.929 | |
| Sex | 0.336 | ||||
| female | 128 | 92 (44%) | 36 (51%) | ||
| male | 154 | 119 (56%) | 35 (49%) | ||
| Pathological tumor size (pT) | 0.113 | ||||
| 1 | 8 | 6 (4%) | 2 (4%) | ||
| 2 | 32 | 29 (19%) | 3 (6%) | ||
| 3 | 161 | 117 (76%) | 44 (88%) | ||
| 4 | 3 | 2 (1%) | 1 (2%) | ||
| Pathological lymph node status (pN) | 0.292 | ||||
| negative | 62 | 50 (33%) | 12 (24%) | ||
| positive | 139 | 102 (67%) | 37 (76%) | ||
| Pathological type | 1.000 | ||||
| ductal | 422 | 341 (93%) | 81 (93%) | ||
| other | 31 | 25 (7%) | 6 (7%) | ||
| Pathological tumor grade | 0.511 | ||||
| 1 | 33 | 26 (17%) | 7 (14%) | ||
| 2 | 102 | 79 (53%) | 23 (47%) | ||
| 3 | 63 | 44 (30%) | 19 (39%) | ||
| Surgery | 1.000 | ||||
| no | 1 | 1 (0%) | 0 (0%) | ||
| yes | 452 | 365 (100%) | 87 (100%) | ||
| Bailey's molecular subtypes | 1.00E-04 | ||||
| ADEX* | 109 | 95 (26%) | 14 (16%) | ||
| immunogenic | 69 | 53 (14%) | 16 (18%) | ||
| pancreatic progenitor | 101 | 93 (25%) | 8 (9%) | ||
| squamous | 174 | 125 (34%) | 49 (56%) | ||
| Median DFS follow-up, months (range) | 254 | 9.86 (1-84) | 1.30 (1-24) | 1.77E-05 | |
| 2-year DFS | 254 | 37% [0.3-0.46] | 14% [0.07-0.31] | 3.19E-04 | |
| Median OS follow-up, months (range) | 254 | 9.53 (1-84) | 2.99 (1-31) | 4.14E-05 | |
| 2-year OS | 254 | 50% [0.42-0.6] | 22% [0.11-0.42] | 7.06E-05 | |
*
ADEX, aberrantly differentiated endocrine exocrine